Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.

Safety 52

Safety Hemp Research and Development Data 52

Veriheal

NOVEMBER 30, 2021

Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. In 2008, he published psychedelic safety guidelines.

Research and Development 98

Research and Development Therapy Data Treatment 98

Veriheal

FEBRUARY 19, 2021

The lack of research is one of the many reasons that cannabis remains federally illegal. But one of the barriers to conducting the necessary research is its federally illegal status. These intertwining factors plaguing cannabis research must be eradicated for the sake of medical cannabis consumers. .

Legalization 94

Legalization Research and Development Safety Data 94

Cannabis Law Report

JULY 8, 2021

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. Acumen Research and Consulting confirmed TNF-? President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. . – July 28, 2021) – PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.

Safety 52

Safety Cannabinoids Events Data 52

The Joint Blog

JULY 25, 2024

This article explores recent research on cannabis and mental health, examining both the benefits and risks associated with its use. Long-term or heavy use of THC has been linked to an increased risk of developing psychiatric disorders such as psychosis and schizophrenia.

Research and Development 26

Research and Development THC CBD Cannabis 26

Cannabis Law Report

SEPTEMBER 23, 2021

BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). This data will assist Awakn’s progress by enabling a better design and more efficient execution of its clinical program.

Research and Development 52

Research and Development Therapy Treatment Data 52

Veriheal

JANUARY 16, 2024

Let’s take a closer look at this new research around CBD for Cerebral Palsy and examine the extent of this trend and its implications for the future of CP management. It occurs due to abnormalities or damage to the developing brain before, during, or after birth. What is Cerebral Palsy?

Patients 113

Patients CBD Treatment Research and Development 113

Cannabis Law Report

MAY 9, 2022

Preferred candidates will have seven years prior experience in a policy-related management role; experience with professional exposure to the cannabis industry or policy issues related to public health and safety; experience with a strong analytical background and experience working with large data sets.

Policy 52

Policy Research and Development Safety Data 52

Cannabis Law Report

SEPTEMBER 9, 2021

WHAT: During the session, “ Cannabis Moves Toward the Mainstream ,” Nielsen will share IRI and BDSA’s predictions for mainstream market opportunities, cannabis ingredients, product development, labeling and safety. . . WHEN: Cross Channel Measurement in a Time of Data Collection Challenges. . 20, 2021, from 2:40 – 2:55 p.m.

Events 102

Events Wellness and Beauty Data Media 102

Veriheal

NOVEMBER 21, 2023

Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy. Maya worked with a group of her peers to develop the buddie Bluetooth cannabis bowl.

Research and Development 108

Research and Development Consumption Education Data 108

Cannabis Law Report

NOVEMBER 10, 2021

– Multiple Contracts Awarded to Support the Development and Manufacturing of Envelta (NES100) – BERWYN, Pa.–(BUSINESS as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. –(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

JANUARY 27, 2020

We take a look at where CBD regulation might be going and whether we should be concerned about safety writes Rob Verkerk PhD, scientific and executive director, ANH-Intl. We take a look at where CBD regulation might be going and whether we should be concerned about safety. A new ‘problem’: safety. ? A new ‘problem’: safety.

Safety 59

Safety CBD Food Seed-To-Sale 59

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. About RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 10, 2021

–(BUSINESS WIRE)– PSI Labs , an Ann Arbor, Michigan-based ISO 17025 accredited Safety Compliance Facility that provides essential cannabis testing services, today announced its expansion into Southern California with the acquisition of pH Solutions, LLC. Monrovia-Based Lab Acquisition Strengthens Cannabis Testing In California.

Research and Development 105

Research and Development Compliance Compliance Safety 105

Cannabis Law Report

AUGUST 22, 2021

But for now, the developers are focused on creating a training that emphasizes compassionate response, de-escalation, and the safety and well-being of individuals having a challenging time with a psychedelic experience. Interesting piece from Lucid news. Read the full report at .

Research and Development 105

Research and Development Decriminalization Education Safety 105

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JULY 28, 2021

Producing deep-dive policy and operational research and analysis on priority initiatives. Collaborating with County departments, community leaders and other agencies to obtain data, provide analysis and convey results that support the Supervisor’s policy agenda. Present materials in a digestible way for different audiences.

Policy 105

Policy Legislation Research and Development Data 105

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We The Maya platform empowers psychedelic researchers, providers, and participants to collectively chart psychedelic best practices.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

OCTOBER 29, 2021

Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use. Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin. DENVER, Oct.

Pharmaceutical 52

Pharmaceutical Research and Development Data Safety 52

Veriheal

MARCH 14, 2022

Cannabis and driving could be a recipe for disaster, say researchers from the Center for Medicinal Cannabis Research in the University of California San Diego. . hours post smoking,” wrote the researchers responsible for carrying out this two-year randomized trial study. . Although performance was improving at 3.5

Research and Development 98

Research and Development Consumption THC Concentrates 98

Veriheal

DECEMBER 23, 2022

Researchers Inspected Cannabis Products for Contaminants. Dr. Maxwell’s team also collected data contained in samples sourced from California. There was more inconsistency in cannabis-borne contaminant regulation as compared with other agricultural commodities,” wrote the researchers. As per the results, 2.3% for extracts.

Research and Development 96

Research and Development Agriculture Data Extraction 96

Cannabis Law Report

FEBRUARY 13, 2022

The Program Specialist 2 (Cannabis) positions will perform applicant and licensee inspection of physical facilities, adherence to program regulations, development of guidance documents and statement of findings and other duties ensuring licensees are complying with public health and safety best practices. Additional Comments.

Programs 52

Programs Research and Development Seed-To-Sale Compliance 52

Cannabis Law Report

MARCH 17, 2022

Data Manager. The Data Manager, under the direction of the Director of Data Analytics, will be responsible for managing, manipulating, analyzing, and modeling data to support the Commission’s research agenda, licensing, and compliance decisions. Request for Responses (RFR): External Research Review.

Compliance 52

Compliance Compliance Research and Development Data 52

Cannabis Law Report

NOVEMBER 9, 2021

Pavel Otáhal, contributing author and Head of the Gene Immunotherapy Research Department at ÚHKT, stated, “Our study compares the manufacture of CAR19 T-cells via PCR-made transposon DNA (LinearDNA) with mRNA encoding of the transposase against a conventional plasmid approach. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

MMJ Recs

MARCH 16, 2024

Economic Growth and Job Creation of the medical marijuana industry The medical cannabis sector serves as a catalyst for economic expansion and workforce development in regions where it’s legalized. Moreover, ensuring product quality and safety throughout the supply chain is paramount to maintain patient trust and regulatory compliance.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

AUGUST 11, 2021

HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. With a strong focus on research and development, HempFusion has an additional 30 products under development.

Research and Development 105

Research and Development Tincture Food Hemp 105

Cannabis Law Report

MAY 26, 2022

Successful Behavioral Addiction Study Supplied Data for Patent. The successful completion of Awakn’s behavioral addictions study was announced last week and the data provided from the study was used in the patent filing. The treatment was also well tolerated with no safety concerns. Awakn Life Sciences Corp. (

Treatment 52

Treatment Research and Development Therapy Data 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Still, research is ongoing. Parkinson’s disease and cannabis. The effectiveness of cannabis for Parkinson’s disease.

Patients 89

Patients Clinical Trials Research and Development Treatment 89

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech will use Ksana Health’s Effortless Assessment Research System (EARS), an end-to-end solution for mobile sensing, to collect passive mobile device meta data from clinical trial participant’s smartphones, in order to identify individual signals of potential response and relapse. Ksana Health – www.ksanahealth.com.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

MARCH 7, 2020

hemp farmers are denied profitable markets for their crops, while unregulated products continue to proliferate, with no safeguards for public health and safety. With regard to adding CBD to food and beverages, FDA maintains that the data currently available raises safety concerns and encourages parties to share relevant information with FDA.

Hemp 71

Hemp CBD Research and Development Safety 71

Cannabis Law Report

OCTOBER 13, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. An abundance of science and public health data supports it.

Research and Development 52

Research and Development Therapy Access Data 52

Canna Law Blog

JULY 25, 2019

For the past six months, the federal agency has been bombarded with messages, urging the FDA to promptly develop a regulatory pathway for the lawful use of hemp-derived CBD (“Hemp-CBD”) in foods and dietary supplements. The Food and Drug Administration (“FDA”) seems to be listening.

CBD 99

CBD Research and Development Hemp Food 99